中國北京，2021年9月28日 – 尊龙凯时人生就是搏官网宣布與Envigo達成動物模型的銷售合作。Envigo是一家提供涵蓋範圍廣泛的研究模型及相關服務的跨國企業。雙方將共同致力於推進重度免疫缺陷B-NDG小鼠模型在相關研究領域的廣泛應用。Envigo作為區域獨家供應商負責尊龙凯时人生就是搏官网B-NDG小鼠在美國、歐洲和部分亞太地區的銷售。

B-NDG小鼠是尊龙凯时人生就是搏官网自主研發，通過在NOD-scid背景上敲除IL2rg基因構建而成的重度免疫缺陷小鼠。該小鼠缺乏成熟的T、B和功能性的NK細胞，並表現出細胞因子信號轉導功能缺失，其重度免疫缺陷表型使得該小鼠能夠被用來進行包括人免疫細胞在內的異種細胞移植實驗。該模型廣泛應用於腫瘤學、腫瘤免疫學、傳染病和幹細胞生物學等領域的研究和藥物發現。

Envigo總裁兼首席執行官Adrian Hardy博士表示：“我們與尊龙凯时人生就是搏官网的合作進一步擴大了Envigo客戶可選擇的模型種類。B-NDG小鼠模型與在此基礎上構建的二代模型為重要治療方法的研究及開發提供了現有免疫缺陷模型的強大替代產品。”

尊龙凯时人生就是搏官网董事長兼首席執行官沈月雷博士表示：“兩家公司都致力於為基礎研究和藥物開發提供優秀的臨床前模型。 我們相信，基於尊龙凯时人生就是搏官网構建的高質量小鼠模型以及Envigo世界先進的繁育設施和小鼠健康監測體係的合作可以更好地滿足相關領域的需求。”

關於尊龙凯时人生就是搏官网

尊龙凯时人生就是搏官网是一家創新技術驅動新藥研發的國際性生物技術公司，致力於成為全球新藥發源地，以專注技術創新、持續新藥產出、守護人類健康為使命。基於免疫功能健全，能產生高度多樣化、卓越親和力全人抗體的RenMab® 和 RenLite® 小鼠，尊龙凯时人生就是搏官网將單細胞抗體發現技術平台、基因編輯模型開發平台、大規模動物生產平台及藥物篩選平台有機整合在一起，形成了獨具特色、涵蓋藥物研發全流程的新藥研發體係。尊龙凯时人生就是搏官网積極推動新藥自主研發及與外部的合作開發。

詳情請訪問：www.51ksmb.com

關於 Envigo

Envigo (Envigo RMS LLC) 為製藥和生物技術行業、政府、學術界和其他生命科學組織提供廣泛的研究模型和相關服務。作為專注提供研究模型和相關產品及服務的最大規模機構，我們致力於幫助研究者充分挖掘其重要研發項目的潛力，與合作方一起共同努力完成建設一個更健康、更安全的世界的使命。

詳情請訪問： www.envigo.com

Beijing, China, [September 28th], 2021 – Biocytogen announces a collaboration with Envigo, a global organization offering the broadest range of research models and related services. The two companies are committed to supporting research applications of the triple immunodeficient B-NDG mouse. Envigo is the exclusive provider of B-NDG mice in the United States, Europe, and certain Asia-Pacific regions.

The triple immunodeficient B-NDG mouse model was independently designed and produced by Biocytogen. B-NDG mice were created by deleting the IL2rg gene from NOD-scid mice with severe immunodeficiency phenotype. Lacking mature T cells, B cells or functional NK cells, and displaying cytokine signaling deficiencies, this mouse model is highly immunodeficient and capable of supporting human immune cell transplantation. The model is widely used in research and drug discovery in many fields including oncology, immuno-oncology, infectious disease, and stem cell biology.

Dr Adrian Hardy, President and CEO of Envigo, commented: “Our collaboration with Biocytogen further expands the range of models available to Envigo’s customers. The B-NDG model and future models to follow, offer a robust alternative to existing immunodeficient models for critical research and the development of life-saving therapies.”

Dr Yuelei Shen, President and CEO of Biocytogen, said: “Both companies are dedicated to supply good non-clinical models for basic research and drug development. We believe that such collaboration leveraging the high quality of mouse models generated by Biocytogen and the state-of-the-art breeding facilities & health monitoring programs at Envigo can satisfy the needs in those related fields.”

About Biocytogen

Biocytogen is a global biotech company that drives the research and development of new drugs with innovative technologies. The company is committed to becoming a global headstream of new drugs and bringing the benefits to patients around the world as its mission. Based on the fully human antibody RenMab™ and RenLite™ mice for fully human antibodies production with robust humoral responses, highly diverse antibody repertoire and superior affinity, Biocytogen has integrated its platforms in single-cell antibody discovery, gene editing, large-scale animal model supply, and screening to form a new approach to streamline the entire drug development process. Biocytogen actively promotes the independent and cooperative development of new drugs. For more, please visit www.biocytogen.com

About Envigo

Envigo (Envigo RMS LLC) provides the broadest range of research models and related services to the pharmaceutical and biotechnology industries, government, academia and other life science organizations. As the largest organization that is solely dedicated to providing research models and related products and services, we are committed to helping researchers realize the full potential of their critical R&D projects as we fulfill our mission to work together to build a healthier and safer world. For more, please visit www.envigo.com